MA39855A - Nouveaux composés de succinate perméables à travers les cellules - Google Patents

Nouveaux composés de succinate perméables à travers les cellules

Info

Publication number
MA39855A
MA39855A MA039855A MA39855A MA39855A MA 39855 A MA39855 A MA 39855A MA 039855 A MA039855 A MA 039855A MA 39855 A MA39855 A MA 39855A MA 39855 A MA39855 A MA 39855A
Authority
MA
Morocco
Prior art keywords
permeable
cell
cells
succinates
atp
Prior art date
Application number
MA039855A
Other languages
English (en)
Other versions
MA39855B1 (fr
Inventor
Karl Henrik Johannes Ehinger
Eskil Elmér
Magnus Joakim Hansson
Steven Moss
Original Assignee
Neurovive Pharmaceutical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58804197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39855(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurovive Pharmaceutical Ab filed Critical Neurovive Pharmaceutical Ab
Publication of MA39855A publication Critical patent/MA39855A/fr
Publication of MA39855B1 publication Critical patent/MA39855B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/28—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C07C327/34—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups with amino groups bound to the same hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/18—Eight-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

La présente invention concerne de nouveaux succinates perméables aux cellules et des précurseurs perméables aux cellules du succinate destinés à augmenter la production d'atp dans les mitochondries. La majeure partie de l'atp produite et utilisée dans la cellule eucaryote provient de la phosphorylation oxydative mitochondriale, processus auquel le cycle de kreb fournit des électrons de haute énergie. Tous les intermédiaires du cycle de kreb ne sont pas facilement perméables à la membrane cellulaire, l'un d'entre eux étant le succinate. La fourniture des nouveaux succinates perméables aux cellules est envisagée pour permettre le passage sur la membrane cellulaire et ainsi les succinates perméables aux cellules peuvent être utilisés pour améliorer la sortie d'atp mitochondrial.
MA39855A 2014-04-08 2015-04-08 Nouveaux composés de succinate perméables à travers les cellules MA39855B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201470190 2014-04-08
EP15714820.6A EP3129016B1 (fr) 2014-04-08 2015-04-08 Nouveaux composés de succinate perméables à travers les cellules
PCT/EP2015/057606 WO2015155231A1 (fr) 2014-04-08 2015-04-08 Nouveaux composés de succinate perméables à travers les cellules

Publications (2)

Publication Number Publication Date
MA39855A true MA39855A (fr) 2018-10-24
MA39855B1 MA39855B1 (fr) 2018-10-31

Family

ID=58804197

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44092A MA44092B1 (fr) 2014-04-08 2015-04-08 Nouveaux composés de succinate perméables à travers les cellules
MA39855A MA39855B1 (fr) 2014-04-08 2015-04-08 Nouveaux composés de succinate perméables à travers les cellules

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA44092A MA44092B1 (fr) 2014-04-08 2015-04-08 Nouveaux composés de succinate perméables à travers les cellules

Country Status (25)

Country Link
US (2) US11147789B2 (fr)
EP (2) EP3391941B1 (fr)
JP (4) JP7082861B6 (fr)
KR (1) KR102322543B1 (fr)
CN (1) CN106458957B (fr)
AU (2) AU2015243346C9 (fr)
CA (1) CA2944565C (fr)
CY (1) CY1120650T1 (fr)
DK (1) DK3129016T3 (fr)
EA (1) EA035678B1 (fr)
ES (2) ES2953522T3 (fr)
HR (1) HRP20181126T1 (fr)
IL (1) IL247904B (fr)
LT (2) LT3129016T (fr)
MA (2) MA44092B1 (fr)
MX (1) MX378072B (fr)
PL (1) PL3129016T3 (fr)
PT (2) PT3129016T (fr)
RS (1) RS57624B1 (fr)
SG (1) SG11201607907PA (fr)
SI (1) SI3129016T1 (fr)
SM (1) SMT201800429T1 (fr)
TR (1) TR201810411T4 (fr)
WO (1) WO2015155231A1 (fr)
ZA (1) ZA201606608B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106255509A (zh) 2014-04-08 2016-12-21 纽维制药有限公司 用于在归因于线粒体氧化磷酸化的复合体i相关损伤的乳酸性酸中毒或药物诱导的副作用的治疗中应用的琥珀酸酯前药
ES2953522T3 (es) * 2014-04-08 2023-11-14 Abliva Ab Compuestos de succinato novedosos con permeabilidad celular
KR20160143731A (ko) * 2014-04-08 2016-12-14 뉴로바이브 파마슈티컬 에이비 Atp 생산을 증가시키기 위한 숙신산 프로드러그
WO2017060422A1 (fr) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Métabolites protégés à base d'acide carboxylique pour le traitement des troubles mitochondriaux
WO2017060400A1 (fr) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Métabolites protégés à base d'acide carboxylique pour le traitement des maladies liées à des dysfonctions mitochondriales
WO2017060418A1 (fr) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Métabolites protégés à base d'acide carboxylique pour le traitement des maladies liées aux mitochondries
WO2017096270A1 (fr) 2015-12-03 2017-06-08 The Regents Of The University Of California Méthodes de traitement de maladies mitochondriales
EP3863596A4 (fr) * 2018-10-11 2022-08-10 Imbria Pharmaceuticals, Inc. Compositions et procédés de traitement et de prévention de la neuropathie optique héréditaire de leber
JP2022504584A (ja) * 2018-10-11 2022-01-13 インブリア ファーマシューティカルズ， インコーポレイテッド Ｔｃａ回路中間体およびその使用方法
CN109675037B (zh) * 2019-01-25 2021-09-14 南方医科大学 Atp及其受体在制备治疗自闭症药物中的应用
IL288990B2 (en) * 2019-06-19 2025-09-01 Abliva Ab Succinate drug meters, preparations containing the succinate drug meters and its uses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB756422A (en) * 1950-09-14 1956-09-05 Saint Gobain Esters of urethanes of glycols and the manufacture thereof
NL6806584A (fr) * 1965-09-20 1968-11-12
FR2265355B1 (fr) 1974-03-28 1977-11-04 Blum Jean
US5112953A (en) * 1989-12-29 1992-05-12 Neorx Corporation Radiolabeled proteins for diagnostic or therapeutic use
DE4101158C2 (de) * 1991-01-14 1994-06-23 Dainippon Ink & Chemicals Wärmehärtbare Reaktionsharzgemische, Verwendung der erfindungsgemäßen Reaktionsharze zur Herstellung von Formkörpern und Beschichtungen
EP0583480A4 (fr) 1992-02-07 1994-03-18 Tsumura & Co Agent d'attenuation des effets secondaires.
JPH07331262A (ja) * 1994-05-31 1995-12-19 Tonen Corp パティキュレート低減用添加剤及び該添加剤を用いたディーゼルエンジン用燃料組成物
CN1222139A (zh) * 1996-06-13 1999-07-07 里奥药物制品有限公司 多元醇琥珀酸酯及其药物制剂
GB9612331D0 (en) * 1996-06-13 1996-08-14 Leo Pharm Prod Ltd Chemical compounds
WO2000001838A2 (fr) 1998-07-02 2000-01-13 The Board Of Regents Of The Leland Stanford Junior University Procedes permettant de fabriquer des polycetides
AUPR059400A0 (en) * 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs
US7727713B2 (en) * 2001-06-20 2010-06-01 Nuevolution A/S Templated molecules and methods for using such molecules
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
KR100791844B1 (ko) 2006-06-30 2008-01-07 주식회사유한양행 메트포르민 또는 그의 염을 함유하는 서방성 제제 및 그의제조방법
KR101069502B1 (ko) 2006-10-31 2011-09-30 (주)아모레퍼시픽 비만 및 당뇨병 개선용 경구용 조성물
US20120308646A1 (en) * 2007-01-18 2012-12-06 Hesheng Zhang Tetracyclic anthraquinones possessing anti-cancer properties
JP2010522762A (ja) 2007-03-26 2010-07-08 サルトリア・フアーマシユーテイカルズ・エル・エル・シー 糖尿病の治療のための方法及びプロブコール誘導体の組成物
US8410139B2 (en) * 2009-10-07 2013-04-02 Bristol-Myers Squibb Company Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
IT1406068B1 (it) 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
JP2014024772A (ja) 2012-07-25 2014-02-06 Univ Of Tokyo ミトコンドリアのａｔｐ産生能昂進剤
ES2661009T3 (es) 2012-10-05 2018-03-27 Neurovive Pharmaceutical Ab Succinatos protegidos para mejorar la producción de ATP mitocondrial
CN106255509A (zh) 2014-04-08 2016-12-21 纽维制药有限公司 用于在归因于线粒体氧化磷酸化的复合体i相关损伤的乳酸性酸中毒或药物诱导的副作用的治疗中应用的琥珀酸酯前药
ES2953522T3 (es) * 2014-04-08 2023-11-14 Abliva Ab Compuestos de succinato novedosos con permeabilidad celular
KR20160143731A (ko) 2014-04-08 2016-12-14 뉴로바이브 파마슈티컬 에이비 Atp 생산을 증가시키기 위한 숙신산 프로드러그

Also Published As

Publication number Publication date
JP7229189B2 (ja) 2023-02-27
EP3391941A1 (fr) 2018-10-24
EP3391941B1 (fr) 2023-06-07
EA201692017A1 (ru) 2017-02-28
KR20160142861A (ko) 2016-12-13
KR102322543B1 (ko) 2021-11-04
JP7082861B2 (ja) 2022-06-09
SI3129016T1 (sl) 2018-10-30
IL247904A0 (en) 2016-11-30
TR201810411T4 (tr) 2018-08-27
JP2021169519A (ja) 2021-10-28
JP2021169518A (ja) 2021-10-28
IL247904B (en) 2020-08-31
CY1120650T1 (el) 2019-12-11
CA2944565C (fr) 2022-11-29
AU2015243346C1 (en) 2019-02-07
LT3391941T (lt) 2023-11-10
SMT201800429T1 (it) 2018-09-13
MX378072B (es) 2025-03-10
US20170105961A1 (en) 2017-04-20
CN106458957B (zh) 2020-08-18
CN106458957A (zh) 2017-02-22
JP2017513829A (ja) 2017-06-01
MX2016012691A (es) 2016-12-16
US11147789B2 (en) 2021-10-19
AU2018282308B2 (en) 2020-04-30
PL3129016T3 (pl) 2018-10-31
US12310940B2 (en) 2025-05-27
BR112016023086A8 (pt) 2021-06-29
EA035678B1 (ru) 2020-07-24
LT3129016T (lt) 2018-09-10
AU2015243346C9 (en) 2019-03-07
PT3391941T (pt) 2023-08-24
AU2015243346B2 (en) 2018-10-18
JP2020100628A (ja) 2020-07-02
BR112016023086A2 (pt) 2017-08-15
EP3129016B1 (fr) 2018-06-06
ZA201606608B (en) 2022-10-26
EP3129016A1 (fr) 2017-02-15
AU2015243346A1 (en) 2016-10-13
US20210401792A1 (en) 2021-12-30
MA44092B1 (fr) 2023-08-31
PT3129016T (pt) 2018-10-01
AU2018282308A1 (en) 2019-01-17
HRP20181126T1 (hr) 2018-10-05
ES2683860T3 (es) 2018-09-28
RS57624B1 (sr) 2018-11-30
MA39855B1 (fr) 2018-10-31
WO2015155231A1 (fr) 2015-10-15
CA2944565A1 (fr) 2015-10-15
ES2953522T3 (es) 2023-11-14
SG11201607907PA (en) 2016-10-28
DK3129016T3 (en) 2018-09-03
HK1255109A1 (en) 2019-08-02
JP7082861B6 (ja) 2023-12-22

Similar Documents

Publication Publication Date Title
MA39855B1 (fr) Nouveaux composés de succinate perméables à travers les cellules
CL2017002154A1 (es) Conjunto de diafragma-electrodo para uso en electrolizadores de agua alcalina
CL2019001568A1 (es) Un acoplador biespecifico de células t que comprende un primer dominio que se une a la región constante de tcr beta 1 (trbc1) o trbc2, y un segundo dominio capaz de activar una célula t. (divisional solicitud 201803096)
EP3830888A4 (fr) Électrodes négatives pour cellules électrochimiques
IL283607A (en) Immunotherapies using enhanced ipsc derived effector cells
EP3697965A4 (fr) Améliorations apportées à des cellules structurales, matrices et procédés d'assemblage
MA39856A (fr) Promédicaments d'acide succinique pour augmenter la production d'atp
TWD198905S (zh) 無柵線太陽能電池
TWD201824S (zh) 太陽能電池
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
MX2018009493A (es) Uso combinado de al menos una endoproteasa y al menos una exoproteasa en un proceso simultaneo de sacarificacion y fermentacion (ssf) para mejorar la produccion de etanol.
MY186789A (en) Cathode assembly for the production of aluminum
CL2017001103A1 (es) Ánodo para el desprendimiento electrolítico de cloro
PH12018502061A1 (en) Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
MX2018004280A (es) Celda electroquimica tubular de oxido solido tubular soportada por electrodos.
IL299405A (en) Methods for deriving dopaminergic neurons from pluripotent stem cells
ZA202204993B (en) Expression of nitrogenase polypeptides in plant cells
PL3728698T3 (pl) Elektroda dyfuzyjna gazowa, instalacja elektrolityczna oraz sposób eksploatacji instalacji elektrolitycznej
MX2021010820A (es) Expresión de polipéptidos de nitrogenasa en células vegetales.
Ekka et al. Spider diversity of Ram Jharna, Raigarh district, Chhattisgarh, India
MX2016012102A (es) Metodos relacionados con celulas pluripotentes.
IL286148A (en) Stat3 transcriptome for designing more potent nk cells
TWD201820S (zh) 無柵線太陽能電池
IL288301A (en) Methods of culturing human pluripotent cells
EP3370740A4 (fr) Enrichissement et amplification de cellules souches mésenchymateuses humaines très puissantes à partir de populations de cellules âgées